Artemether+lumefantrine Tablets are used to treat acute, uncomplicated malaria infections caused by Plasmodium falciparum in patients aged 2 months and up who weigh more than 5 kg. Artemether+lumefantrine Tablets have been demonstrated to be effective in areas where chloroquine resistance has been documented.

Malaria

• The dosage of Artemether+Lumefantrine is as follows-
  • 5 to < 15 kg: 1 tablet
  • 15 to < 25 kg: 2 tablets
  • 25 to < 35 kg: 3 tablets
  • 35 kg and over: 4 tablets
• Each tablet contains 120 mg lumefantrine and 20 mg artemether.
• This medication should be taken with food & maybe crushed while taking.
• Tablets should be administered over 3 days for a total of 6 doses: an initial dose, second dose after 8 hours and then twice-daily (morning and evening) for the following 2 days.

Artemether+Lumefantrine may cause the following side effects-

• headache
• anorexia
• dizziness
• asthenia
• arthralgia
• myalgia

Headache	Anorexia	Dizziness
Asthenia	Arthralgia	Myalgia

The most common adverse reactions in children (greater than 12%) are pyrexia, cough, vomiting, anorexia, and headache.

• Patients with known QT prolongation, hypokalemia or hypomagnesemia, and those taking other drugs that prolong the QT interval should avoid using artemether+lumefantrine.
• Halofantrine and Artemether+lumefantrine Tablets should not be administered within one month of each other due to potential additive effects on the QT interval.
• Due to limited safety data, antimalarials should not be given concurrently unless there are no other treatment options.
• Following artemether+lumefantrine tablets, QT prolonging drugs such as quinine and quinidine should be used with caution.
• Substrates, inhibitors, or inducers of CYP3A4, including antiretroviral medications, should be used with caution with Lumefantrine (along with artemether) Tablets due to the possibility of decreased efficacy or additive QT prolongation.